FUJIFILM Healthcare Americas Corporation and mTuitive have announced a strategic partnership to connect mTuitive’s structured pathology reporting platform with Fujifilm’s Synapse® Pathology PACS, creating a direct pipeline from the pathology lab into enterprise imaging. The integration is available now for organizations using both platforms.
HotSpot Take
FUJIFILM Healthcare Americas Corporation and mTuitive, both headquartered in Massachusetts, have partnered to integrate mTuitive’s structured synoptic pathology reporting platform with Fujifilm’s Synapse Pathology PACS. Structured reports (including CAP- and Commission on Cancer-compliant synoptic data and biomarker information) will automatically flow through the Laboratory Information System into Synapse, giving oncology, radiology, and pathology teams unified access to diagnostic data in real time. The integration is available now for organizations already using both platforms.
Closing the Gap Between Pathology and Enterprise Imaging
A multidisciplinary care team reviews diagnostic imaging and pathology data. Integrating structured pathology reports with enterprise imaging platforms supports more coordinated decision-making in settings like tumor boards.
Pathology reports have long operated in a separate silo from radiology imaging systems, a structural gap with direct consequences for multidisciplinary care. When a tumor board convenes, oncologists, radiologists, and surgeons ideally need access to both imaging and pathology findings simultaneously. In practice, those two data streams often live in different systems, requiring manual retrieval and creating opportunities for errors or delays.
The Fujifilm-mTuitive integration is designed to address that gap. mTuitive, a Centerville, Massachusetts-based provider of synoptic reporting solutions, produces structured pathology reports using its CAP eFRM platform, which captures discrete data elements at the point of sign-out rather than generating unstructured narrative text. Those structured reports, covering CAP Cancer Protocol checklists, Commission on Cancer synoptic requirements, and biomarker data, will now automatically flow through the Laboratory Information System (LIS) into Fujifilm’s Synapse Pathology, where imaging teams can access them alongside whole-slide images.
“By integrating mTuitive’s structured reporting capabilities with Synapse’s Pathology, our robust, open-cloud accessible platform, we’re empowering healthcare teams with the unified diagnostic insights they need to deliver faster, more coordinated patient care.” — Dr. Mark Lloyd, Vice President of Digital Pathology, FUJIFILM Healthcare Americas Corporation
“By integrating mTuitive’s structured reporting capabilities with Synapse’s Pathology, our robust, open-cloud accessible platform, we’re empowering healthcare teams with the unified diagnostic insights they need to deliver faster, more coordinated patient care,” said Dr. Mark Lloyd, Vice President of Digital Pathology at FUJIFILM Healthcare Americas Corporation.
What Structured Reporting Means for Clinical Teams
The distinction between narrative and structured pathology reports matters more than it might appear. A narrative report reads as free text, clinical prose written by the pathologist, while a synoptic or structured report organizes findings into discrete, standardized data fields. The structured approach enables downstream uses that prose cannot support easily: cancer registry reporting, quality metrics tracking, research queries, and input to AI models.
FUJIFILM Healthcare Americas Corporation’s Synapse Pathology is an FDA-cleared digital pathology PACS that supports whole-slide image management across multiple scanning vendors. The platform already serves as a centralized image repository for health systems managing high volumes of pathology cases. Fujifilm signaled an expanded focus on pathology and non-radiology AI at HIMSS26 in March, and this partnership is a concrete step in that direction. By pulling mTuitive’s structured reports into Synapse automatically after sign-out, the integration preserves the LIS as the system of record while making pathology data available to clinicians who work primarily in imaging environments.
Key capabilities of the combined workflow include unified real-time access to final pathology reports across care teams, structured pathology data appearing alongside radiology images in tumor board settings, elimination of duplicative data entry between systems, and downstream use of structured data for cancer registries, clinical analytics, and AI applications.
“As we deepen our alliance with Fujifilm, we are intentionally building an ecosystem where imaging, pathology, and informatics work in concert to give care teams faster, more confident answers for their patients.” — Hans Wernke, Vice President of Strategic Alliances, mTuitive
“As we deepen our alliance with Fujifilm, we are intentionally building an ecosystem where imaging, pathology, and informatics work in concert to give care teams faster, more confident answers for their patients,” said Hans Wernke, Vice President of Strategic Alliances at mTuitive.
Tumor Boards as the Clinical Test Case
Tumor board meetings represent one of the clearest clinical use cases for this type of integration. Multidisciplinary teams reviewing cancer cases benefit directly from having imaging and pathology findings available in the same environment, reducing the friction of switching between systems and ensuring that all participants work from the same current data.
The College of American Pathologists and the Commission on Cancer, whose reporting standards mTuitive’s platform is built to satisfy, have long promoted standardized synoptic reporting as a tool for improving cancer care quality. Having that standardized data automatically surfaced in an enterprise imaging environment extends its utility beyond the laboratory itself.
mTuitive has been active in building partnerships around structured reporting. In March 2026, the company announced an integration with Ibex Medical Analytics to embed AI-powered diagnostic insights directly into its synoptic reporting workflow, another step toward making structured pathology data a richer input to clinical decision-making.
A Market in Early-Stage Transition
The Fujifilm-mTuitive partnership arrives at a moment when U.S. health systems are still in the earliest phases of digital pathology adoption. According to KLAS Research’s Digital Pathology 2026 report, published in February 2026, fewer than 15% of U.S. healthcare organizations have selected a digital pathology vendor and are at various stages of deployment. That figure underscores both the opportunity ahead and the challenge: the majority of U.S. pathology departments are still operating on glass slides and narrative reporting, which means the structured data pipeline this integration enables does not yet exist at most institutions.
The KLAS report also identified a meaningful performance gap between vendors. Pathology-native vendors are currently outperforming traditional radiology PACS vendors in early customer satisfaction, with organizations praising purpose-built platforms and strategic guidance. Traditional imaging vendors, including Sectra, Philips, and Fujifilm, showed solid but more variable results. For Fujifilm, that finding creates strategic pressure: the company’s core strength lies in enterprise imaging, and translating that strength into clinical pathology credibility requires more than digitizing slides. Integrating structured reporting through a specialist partner like mTuitive is a practical response to that gap.
On the structured reporting side, mTuitive occupies a relatively distinct position. The company’s CAP eFRM platform was developed in partnership with the College of American Pathologists and is designated as MEDITECH’s recommended synoptic reporting solution. Its integrations span Epic, Oracle Health, Clinisys, and other major LIS and EHR platforms, making it broadly embedded in existing pathology workflows at the institutions where it operates. Competing synoptic reporting tools exist within broader LIS platforms (Oracle Health’s CoPathPlus and PowerPath, for instance, include CAP-compliant structured reporting capabilities), but mTuitive’s position as a dedicated, standards-body-aligned specialist has made it a common choice for organizations that prioritize compliance and data completeness.
The broader digital pathology competitive landscape involves distinct layers. Scanner hardware is dominated by Leica Biosystems (Aperio), which holds the most widely adopted FDA-cleared clinical scanner in the U.S. market. Image management systems are increasingly contested territory, with pathology-native vendors like Proscia and PathAI competing alongside radiology-rooted platforms from Sectra, Philips, and Fujifilm. The integration of structured reporting into the image management layer is still uncommon, which is part of what makes the Fujifilm-mTuitive announcement notable: it extends the value of the pathology PACS beyond image storage and viewing into the clinical data layer.
mTuitive’s recent activity suggests deliberate ecosystem expansion before that layer becomes table stakes. Beyond the Fujifilm partnership, the company announced an integration with Ibex Medical Analytics in March 2026 to embed AI-powered diagnostic insights directly into its synoptic reporting workflow. The pattern points toward mTuitive positioning its structured reporting platform as a connective layer across imaging, informatics, and AI rather than a standalone compliance tool.
Availability and Implementation
The integration is available now for health systems already operating both Fujifilm’s Synapse Pathology and mTuitive’s platform. According to the companies, organizations can leverage greater value from existing systems without implementing new platforms, avoiding the implementation burden often associated with cross-system integrations.
For patients, the practical implication is care teams that are better coordinated at key decision points, particularly in oncology, where treatment planning depends on rapid, accurate interpretation of both imaging findings and pathology results. When radiologists, oncologists, and pathologists operate from the same structured data in the same environment, diagnostic confidence improves and delays in treatment decisions are reduced.
— This original article was created with AI support.
